The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma.
Chong-Chang ZhouJinyun LiQun LiHuigao LiuDong YeZhenhua WuZhisen ShenHongxia DengPublished in: Journal of clinical laboratory analysis (2019)
In summary, our study reveals that HOXA9 promoter hypermethylation contributes to the risk of HNSCC and its progression and metastasis. Additionally, HOXA9 hypermethylation is a potential biomarker for the early diagnosis and screening of patients with HNSCC.